Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397529 | 0.81 | FFAR1 (0.45) | FFAR1LMNAL3MBTL1ITGB3ITGA2B | |
| SCHEMBL3399524 | 0.78 | ITGB3 (0.46) | FFAR1LMNAL3MBTL1ITGB3ITGA2B | |
| SCHEMBL3400701 | 0.78 | ITGB3 (0.46) | FFAR1LMNAL3MBTL1ITGB3ITGA2B | |
| SCHEMBL3403396 | 0.77 | FFAR1 (0.43) | FFAR1LMNAL3MBTL1ITGB3ITGA2B | |
| SCHEMBL3402227 | 0.76 | FFAR1 (0.45) | FFAR1LMNAL3MBTL1ITGB3ITGA2B | |
| SCHEMBL3402019 | 0.76 | FFAR1 (0.45) | FFAR1LMNAL3MBTL1ITGB3ITGA2B | |
| SCHEMBL3402949 | 0.76 | FFAR1 (0.44) | FFAR1LMNAL3MBTL1ITGB3ITGA2B | |
| SCHEMBL3064902 | 0.76 | PARP15 (0.57) | FFAR1LMNAL3MBTL1ITGB3ITGA2B | |
| SCHEMBL14903039 | 0.75 | LMNA (0.48) | FFAR1LMNAL3MBTL1ITGB3ITGA2B | |
| SCHEMBL3399633 | 0.74 | FFAR1 (0.42) | FFAR1LMNAL3MBTL1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299090-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299090-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2684861-A2 | Spiro compounds and pharmaceutical use thereof | Japan Tobacco Inc. (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-20130109710-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-20130109710-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-8299296-B2 | Spiro compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299296-B2 | Spiro compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2508503-A1 | Spiro compounds and pharmaceutical use thereof | Japan Tobacco, Inc. (JP) | 2012-10-10 | — | — | EP | disclosed |
| EP-2202216-B1 | SPIRO-RING COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | JAPAN TOBACCO INC (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-2202216-A1 | SPIRO-RING COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Japan Tobacco Inc. (JP) | 2010-06-30 | — | — | EP | disclosed |
| US-20090170908-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090170908-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170908-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, PKD2 | FFAR1 2207/4885LMNA 1204/4885L3MBTL1 4874/4885 |
| US-20150299090-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, PKD2 | FFAR1 2207/4885LMNA 1204/4885L3MBTL1 4874/4885 |
| US-20130109710-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, PKD2 | FFAR1 2207/4885LMNA 1204/4885L3MBTL1 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.